Aptose Reports Third Quarter 2025 Results
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose LevelsPatients are Now Being Treated at 160 mg Dose of Tuspetinib SAN DIEGO and TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) --...
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of...
New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth HALIFAX, Nova Scotia, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Appili...
Pacvue Partners with Amazon Ads Japan to Host Hackathon for Agencies...
Six advertising agencies and brands will compete for a $20,000 grand prize during the new hackathon, taking place on November 20 at the Shangri La Hotel in TokyoTOKYO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Pacvue, the industry's first AI-powered Commerce Operating System, today announced that with sponsorship...
New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less...
Second study to be presented at the 2nd European Congress on Dermato-Oncology demonstrates DecisionDx-Melanoma can identify patients with a negative sentinel lymph node who have a higher risk of poor outcomesFRIENDSWOOD, Texas, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health...
